Radnet Stock Price, News & Analysis

RadNet (NASDAQ: RDNT), a leading national provider of diagnostic imaging services, announced that Executive Vice President and CFO Mark Stolper will present at the Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for May 13, 2025, at 5:00 p.m. Pacific Time at the Encore Hotel in Las Vegas, NV.

RadNet operates 398 outpatient imaging centers across eight states including Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas. The company provides diagnostic imaging services, radiology information technology, AI solutions through DeepHealth, and teleradiology services. RadNet employs over 11,000 people, including contracted radiologists, full-time and per diem employees, and technologists.

GE HealthCare (GEHC) will showcase its latest breast health technology advancements at the 2025 Society of Breast Imaging Symposium in Colorado Springs. The company is featuring several key innovations:

The Pristina Via™ mammography system offers streamlined workflows with zero-click acquisition, no wait time between exposures, and faster DBT image-to-image cycle times. The company will distribute DeepHealth's SmartMammo™, an AI-powered solution for breast cancer screening, now commercially available in the U.S.

Additional innovations include the Invenia™ ABUS Premium, the first FDA-approved breast ultrasound for dense breast detection, showing a 35.7% increase in cancer detection when used with mammography. The company also presents SenoBright™ HD and SerenaBright™, the first FDA-cleared Contrast Enhanced Mammography and CEM biopsy solutions.

RadNet Inc (NASDAQ: RDNT), a national leader in providing diagnostic imaging services through owned and operated outpatient centers, has scheduled its first quarter 2025 financial results conference call for Monday, May 12, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors can participate by dialing 844-826-3035 (US) or 412-317-5195 (International). The event will feature simultaneous and archived webcasts accessible at the provided ViaVid link. A replay will be available by calling 844-512-2921 (US) or 412-317-6671 (International) using passcode 10199390.

RadNet (NASDAQ: RDNT) has announced the acquisition of iCAD (NASDAQ: ICAD) in an all-stock transaction valued at approximately $103 million. Under the agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each iCAD share, representing $3.61 per share and a 98% premium based on April 14, 2025 closing prices.

The merger combines iCAD's ProFound Breast Health Suite with RadNet's DeepHealth AI-powered breast screening solutions. iCAD's network spans over 1,500 healthcare provider locations across 50 countries, facilitating over 8 million annual mammograms. The integration aims to enhance breast cancer detection accuracy and early diagnosis capabilities.

The transaction, unanimously approved by both companies' boards, is expected to close in Q2 or Q3 2025, subject to iCAD stockholder approval and customary closing conditions.

RadNet (NASDAQ: RDNT), a national leader in diagnostic imaging services, has announced its participation in the upcoming 35th Annual Oppenheimer Healthcare MedTech & Services Conference. The company's Executive Vice President and Chief Executive Officer, Mark Stolper, will deliver a virtual presentation on March 17, 2025, at 12:40 p.m. Eastern Time.

The presentation will be accessible through a live webcast at wsw.com/webcast/oppenheimer40/rdnt/2795776, with replay options available. RadNet operates a network of fully-owned and operated outpatient imaging centers, focusing on providing high-quality, cost-effective diagnostic imaging services.

RadNet (NASDAQ: RDNT) reported strong Q4 2024 financial results with record-breaking performance. Total revenue increased 13.5% to $477.1 million, while Adjusted EBITDA grew 14.0% to $75.0 million compared to Q4 2023. The Digital Health segment showed impressive growth with revenue up 28.1% to $18.9 million.

Key operational highlights include:

• 8.0% increase in aggregate procedural volumes
• 4.0% growth in same-center procedural volumes
• Strong imaging volume growth: MRI +13.4%, CT +13.9%, PET/CT +23.9%
• Expansion to 398 imaging centers, with 38.4% being joint venture facilities

The company maintained a strong financial position with $740 million cash balance and net debt to Adjusted EBITDA ratio under 1.0x. Adjusted Earnings Per Share reached $0.22 in Q4 2024, up from $0.15 in Q4 2023.

RadNet (NASDAQ: RDNT) has announced a strategic partnership with OB/GYN Specialists of the Palm Beaches to launch breast imaging services across multiple locations in Palm Beach County. The collaboration integrates RadNet's DeepHealth AI-powered diagnostic solutions with OB/GYN Specialists, the largest obstetric and gynecological care provider in the region serving 60,000 women annually across 10 locations.

The partnership features RadNet's Enhanced Breast Cancer Detection (EBCD) protocol, which has demonstrated a 21% increase in breast cancer detection rates. The service includes interpretation by RadNet's board-certified breast imaging radiologists and implements DeepHealth's AI-driven health informatics, featuring cloud-based operating systems, patient tracking, and risk assessment integrated with EHR systems.

DeepHealth, a subsidiary of RadNet (NASDAQ: RDNT), will showcase new AI-powered radiology solutions at ECR 2025 in Vienna. The company will introduce Diagnostic Suite™, a cloud-native PACS alternative, and SmartMammo™, an AI-powered mammography solution that has shown a 21% increase in cancer detection rate.

The company's AI-powered Lung solution is currently supporting the NHS England's Lung Cancer Screening Program, where 76% of cancers were detected at earlier stages, compared to 29% historically. Their Prostate solution has demonstrated 97% diagnostic sensitivity and 37% reduction in workflow time for MRI reads.

DeepHealth's solutions are powered by DeepHealth OS, a cloud-native operating system integrating data across various platforms. The company's technology is currently utilized by over 800 clinical sites and more than 3,000 radiologists globally.